A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Rigel Pharmaceuticals

Summary

The primary objective of this study is: • To evaluate the long-term safety of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA).

Eligibility

Age range: 18–100 years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: 1. Subject must be willing and able to give written informed consent by signing an IRB approved Informed Consent Form prior to undergoing any study-specific procedures. 2. Subject must have completed all 24 weeks of participation in the study C-935788-057. Exclusion Criteria: 1\. Any subject who discontinued participation in Study C-935788-057 prior to Week 24.

Locations (37)

University of Southern California - Janice and Robert Hall Clinical Trials Biospecimen Laboratory
Los Angeles, California
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California
Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia
John Hopkins Bayview Medical Center
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada

Summary

Eligibility

Interventions

Locations (37)